Ticker: CRMD

CorMedix Inc. (NYSE: CRMD) has experienced a significant transformation in its financial landscape during Q2 2025, following the commercial launch of its product, DefenCath. Positive Aspects: Revenue Growth: Net sales surged to $39.7 million for the three months ended June 30, 2025, compared to ...

CorMedix Inc. (NYSE: CRMD) has released its financials for the quarter ended March 31, 2025. The company is focused on commercializing its lead product, DefenCath, an FDA-approved antimicrobial catheter lock solution designed to reduce bloodstream infections in patients undergoing chronic hemodia...